Prophylactic efficacy of cephamycin plus fluoroquinolones in high risk patients on inhibiting infectious complications after transrectal prostate biopsy

References

• Shigemura KArakawa SMiura TNakano YTanaka KFujisawa M. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections. Jpn J Infect Dis. 2008;61:226–8.
   PubMed Web of Science ®Google Scholar
• Auer SWojna AHell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:4006–8.
   PubMed Web of Science ®Google Scholar
• Bader MSHawboldt JBrooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122:7–15.
   PubMed Web of Science ®Google Scholar
• Doi AShimada THarada SIwata KKamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2013;17:e159–63.
   PubMed Web of Science ®Google Scholar
• Aldridge KEAshcraft DO'Brien MSanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother. 2003;47:148–53.
   PubMed Web of Science ®Google Scholar
• Shigemura KMatsumoto MTanaka KYamashita MArakawa SFujisawa M. Efficacy of combination use of beta-lactamase inhibitor with penicillin and fluoroquinolones for antibiotic prophylaxis in transrectal prostate biopsy. Korean J Urol. 2011;52:289–92.
   PubMedGoogle Scholar
• Miura TTanaka KShigemura KNakano YTakenaka AFujisawa M. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol. 2008;15:457–9.
   PubMed Web of Science ®Google Scholar
• Suwantarat NDumford DM 3rd, Ponce-Terashima RKundrapu SZabarsky TFZhu H. Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy. Infect Control Hosp Epidemiol. 2013;34:973–6.
   PubMed Web of Science ®Google Scholar
• Liss MAPeeples ANPeterson EM. Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol. 2011;49:1116–8.
   PubMed Web of Science ®Google Scholar
• Steensels DSlabbaert KDe Wever LVermeersch PVan Poppel HVerhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect. 2012;18:575–81.
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn TVasoo SSingh K. Urinary tract infections due to multidrug-resistant Enterobacteriaceae: prevalence and risk factors in a chicago emergency department. Emerg Med Int. 2013;2013:258517.
   PubMedGoogle Scholar
• Hoban DJLascols CNicolle LEBadal RBouchillon SHackel Met al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis. 2012;74:62–7.
   PubMed Web of Science ®Google Scholar
• Tham JOdenholt IWalder MAndersson LMelander E. Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli in a county of southern Sweden. Infect Drug Resist. 2013;6:93–7.
   PubMedGoogle Scholar
• Zhang XYLi QZhou X. The clinical efficacy and safety of intravenous cefmetazole in treatment of 1,522 patients with aspiration pneumonia. Zhonghua Nei Ke Za Zhi. 2011;50:295–8.
   PubMedGoogle Scholar
• Schentag JJ. Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials. Pharmacotherapy. 1991;11:2–19.
   PubMed Web of Science ®Google Scholar
• Lepeule RRuppé ELe PMassias LChau FNucci Aet al. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother. 2012;56:1376–81.
   PubMed Web of Science ®Google Scholar
• Williamson DARoberts SAPaterson DLWilliamson DARoberts SAPaterson DLet al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis. 2012;54:1406–12.
   PubMed Web of Science ®Google Scholar
• Saha SNayak SBhattacharyya ISaha SMandal AKChakraborty Set al. Understanding the patterns of antibiotic susceptibility of bacteria causing urinary tract infection in West Bengal, India. Front Microbiol. 2014;5:463.
   PubMedGoogle Scholar
• Linhares IRaposo TRodrigues AAlmeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis. 2013;13:19.
   PubMed Web of Science ®Google Scholar
• Utrera NMÁlvarez MBPolo JMSánchez ATMartínez JPGonzález RD. Infectious complications after transrectal ultrasound-guided prostatic biopsy. Analysis of our experience. Arch Esp Urol. 2011;64:605–10.
   PubMedGoogle Scholar
• de Lastours VChau FRoy CLarroque BFantin B. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother. 2014;69:3393–400.
   PubMed Web of Science ®Google Scholar
• Chong YShimoda SYakushiji HIto YAoki TMiyamoto Tet al. Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis. PLoS One. 2014;9:e85210.
   PubMed Web of Science ®Google Scholar